Insurance denied your melanoma treatment? We write the appeal that gets it overturned.

What This Guide Covers

This guide helps patients and advocates overturn insurance denials for melanoma treatment—specifically checkpoint inhibitors like Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), and Opdualag (nivolumab + relatlimab); BRAF/MEK targeted combinations like Tafinlar + Mekinist or Braftovi + Mektovi; and newer therapies including Amtagvi (tumor-infiltrating lymphocyte cell therapy), Kimmtrak (for uveal melanoma), and Imlygic (oncolytic virus). Denials are common because melanoma treatment has evolved rapidly—adjuvant immunotherapy for Stage IIB/IIC and Stage III disease only gained FDA approval in 2018–2021, BRAF/MEK combinations require mutation testing that insurers sometimes question, and newer therapies like TIL (approved February 2024) are labeled "experimental" despite accelerated FDA approval. Many plans have not updated their medical policies to reflect current NCCN guidelines, and utilization-management vendors flag high-cost biologics regardless of evidence. This guide walks you through the specific citations, trial data, and counter-arguments that work.

---

Why Insurers Deny Melanoma Immunotherapy and Targeted Therapy

1. "Experimental / Investigational" for FDA-Approved Indications

Insurers classify treatments as experimental even when FDA-approved—especially in the adjuvant setting. Common examples:

• Keytruda for Stage IIB/IIC (FDA December 2021, KEYNOTE-716): denied as "not medically necessary for early-stage disease" despite 17-month recurrence-free survival benefit.
• Amtagvi (lifileucel) TIL therapy (FDA February 16, 2024): denied as "experimental cell therapy" even though it has accelerated approval for advanced melanoma after anti-PD-1 progression.
• Opdualag (nivolumab + relatlimab, FDA March 18, 2022): denied as "investigational combination" despite RELATIVITY-047 trial showing superior progression-free survival versus Opdivo monotherapy.

2. Step-Therapy / "Try Less Expensive Option First"

Plans require sequential steps even when clinical guidelines support first-line use:

• Opdivo + Yervoy combination denied, insurer mandates single-agent Keytruda or Opdivo first—ignoring CheckMate-067 data showing superior overall survival for combination in BRAF wild-type advanced melanoma.
• BRAF/MEK combinations (Tafinlar + Mekinist or Braftovi + Mektovi) denied in favor of single-agent vemurafenib or dabrafenib monotherapy, despite FDA labeling requiring combination (single-agent BRAF leads to resistance within months).
• Kimmtrak for HLA-A\*02:01-positive metastatic uveal melanoma denied, insurer demands trial of Keytruda first—even though uveal melanoma is notoriously immunotherapy-resistant and Kimmtrak (tebentafusp) is the only FDA-approved option (January 25, 2022) with overall survival benefit in IMCgp100-202.

3. Off-Label or Non-Standard Sequencing

Denials when treatment is FDA-approved but requested in a different line or combination:

• Neoadjuvant immunotherapy (Keytruda or Opdivo + Yervoy before surgery for resectable Stage III) denied as "not standard of care" despite NCCN Category 2A recommendation and pathologic complete response rates of 30–45% improving surgical outcomes.
• Imlygic (talimogene laherparepvec) intralesional oncolytic virus denied for in-transit lesions if patient has concurrent distant metastases, even though OPTiM trial included Stage IIIB–IVM1a and FDA approval covers unresectable disease.
• Checkpoint inhibitor after BRAF/MEK progression in BRAF-mutant melanoma: insurer cites DREAMseq trial showing checkpoint-first superior to targeted-first, denying Opdivo + Yervoy after Tafinlar + Mekinist failure—misapplying a sequencing trial to block salvage therapy.

4. "Requires Biomarker / Mutation Not Documented"

Denials pending test results or questioning test validity:

• BRAF V600E/K mutation required for Tafinlar + Mekinist or Braftovi + Mektovi: insurer rejects community pathology BRAF test, demands repeat at insurer-designated lab (delaying treatment weeks).
• HLA-A\*02:01 typing required for Kimmtrak (uveal melanoma): insurer denies coverage of HLA typing itself, then denies Kimmtrak for lack of HLA documentation.
• PD-L1 expression: some plans require PD-L1 ≥1% or ≥50% for Keytruda, importing criteria from lung cancer medical policies even though melanoma FDA approvals and KEYNOTE trials (054, 716) had no PD-L1 threshold.

5. Coding, Site-of-Service, and Formulary Restrictions

Administrative denials unrelated to clinical evidence:

• Medical vs. pharmacy benefit: Keytruda or Opdivo denied under medical benefit, plan states it must be billed under specialty pharmacy—triggering re-authorization with different prior-authorization form and months of delay.
• Inpatient administration requirement: Opdivo + Yervoy combination or Amtagvi TIL infusion approved only if given inpatient, but hospital cannot schedule inpatient bed for outpatient infusion, creating Catch-22.
• Formulary exclusion: plan covers Keytruda but excludes Opdualag (or vice versa) from formulary despite both being anti-PD-1 backbones, forcing switch mid-treatment or at progression.

---

The Citations Insurers Respect

When you appeal, cite these specific guidelines, trials, and policy documents by name and year. Generic statements ("studies show…") are ignored; precise references force medical directors to engage with evidence.

NCCN Clinical Practice Guidelines in Oncology

• NCCN Guidelines: Melanoma: Cutaneous (Version 2.2024 or current year): the U.S. standard of care reference. NCCN is updated 2–3 times per year; cite the most recent version available at NCCN.org (free registration for patients).

- Adjuvant therapy for Stage IIB/IIC: Keytruda (pembrolizumab) Category 1 (KEYNOTE-716).

- Adjuvant therapy for Stage III: Keytruda Category 1 (KEYNOTE-054), Opdivo Category 1 (CheckMate-238), Tafinlar + Mekinist for BRAF V600E/K Category 1 (COMBI-AD).

- Advanced/metastatic first-line: Opdivo + Yervoy (BRAF wild-type preferred, Category 1), Keytruda or Opdivo monotherapy (Category 1), Opdualag (Category 2A), Tafinlar + Mekinist or Braftovi + Mektovi (BRAF V600E/K, Category 1).

- Post-PD-1 progression: Amtagvi (TIL) Category 2A, Imlygic for injectable lesions Category 2A, clinical trial preferred.

• NCCN Guidelines: Uveal Melanoma (Version 1.2024): Kimmtrak (tebentafusp) Category 1 for HLA-A\*02:01-positive metastatic uveal melanoma (first-line preferred over checkpoint inhibitors, which have <5% response rate in uveal).

FDA Approval Letters and Labels

Always cite the specific FDA approval date and indication from the prescribing information (available at DailyMed.nlm.nih.gov or Drugs@FDA):

• Keytruda (pembrolizumab):

- Advanced unresectable/metastatic melanoma: September 4, 2014.

- Adjuvant Stage III: December 19, 2018 (KEYNOTE-054).

- Adjuvant Stage IIB/IIC: December 1, 2021 (KEYNOTE-716).

- Pediatric melanoma ≥12 years: included in label.

• Opdivo (nivolumab):

- Advanced melanoma monotherapy: December 22, 2014 (CheckMate-066).

- Adjuvant Stage III/IV resected: December 20, 2017 (CheckMate-238).

• Opdivo + Yervoy combination:

- Advanced melanoma BRAF wild-type: October 2, 2015; expanded to all advanced melanoma January 2016 and April 2018.

• Opdualag (nivolumab 480 mg + relatlimab 160 mg fixed-dose):

- Advanced melanoma: March 18, 2022 (RELATIVITY-047).

• Tafinlar (dabrafenib) + Mekinist (trametinib):

- Advanced BRAF V600E/K melanoma: January 2014.

- Adjuvant Stage III BRAF V600E/K: April 30, 2018 (COMBI-AD).

• Braftovi (encorafenib) + Mektovi (binimetinib):

- Advanced BRAF V600E/K melanoma: June 27, 2018 (COLUMBUS).

• Imlygic (talimogene laherparepvec):

- Unresectable Stage IIIB–IVM1a melanoma: October 27, 2015 (OPTiM trial).

• Amtagvi (lifileucel):

- Advanced melanoma post-anti-PD-1 ± BRAF/MEK: February 16, 2024, accelerated approval (C-144-01 trial).

• Kimmtrak (tebentafusp-tebn):

- HLA-A\*02:01-positive metastatic uveal melanoma: January 25, 2022 (IMCgp100-202).

Landmark Clinical Trials

Cite trial name, publication, and year:

• KEYNOTE-054 (adjuvant Keytruda Stage III): N Engl J Med 2018; 378:1789–1801 + 4-year update Lancet Oncol 2021.
• KEYNOTE-716 (adjuvant Keytruda Stage IIB/IIC): Lancet 2022; 399:1718–1729.
• CheckMate-238 (adjuvant Opdivo Stage III): N Engl J Med 2017; 377:1824–1835.
• CheckMate-067 (Opdivo + Yervoy vs monotherapy advanced melanoma): N Engl J Med 2017; 377:1345–1356; 6.5-year overall survival update J Clin Oncol 2021.
• COMBI-AD (adjuvant Tafinlar + Mekinist Stage III BRAF V600): Lancet 2017; 390:1849–1862; 5-year update J Clin Oncol 2020.
• RELATIVITY-047 (Opdualag vs Opdivo advanced melanoma): N Engl J Med 2022; 386:24–34.
• DREAMseq (sequencing in BRAF-mutant melanoma): J Clin Oncol 2022; 40:3821–3830 (checkpoint-first superior to targeted-first, but does not say "never use targeted therapy after checkpoint failure").
• OPTiM (Imlygic intralesional): J Clin Oncol 2015; 33:2780–2788.
• C-144-01 (Amtagvi TIL): J Clin Oncol 2022; 40:2650–2660 (36% objective response rate, durable responses).
• IMCgp100-202 (Kimmtrak uveal melanoma): N Engl J Med 2021; 385:1196–1206 (overall survival benefit vs investigator's choice).

Other Authoritative Guidelines

• ASCO Guidelines: Cite when available (e.g., ASCO endorsement of NCCN melanoma guidelines).
• ESMO Clinical Practice Guidelines: Cutaneous Melanoma (European Society for Medical Oncology): often includes therapies NCCN lists as Category 2A; useful for neoadjuvant or non-U.S.-standard sequences.
• CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs): Medicare Advantage and many commercial plans reference CMS. No melanoma-specific NCD currently, but LCD may exist in your MAC jurisdiction—search cms.gov.

---

How to Argue Against Each Denial Reason

1. Defeating "Experimental / Investigational" for FDA-Approved Indications

Concrete steps:

1. Attach the FDA approval letter and current prescribing information (print from DailyMed). Highlight the exact indication, approval date, and that your patient's diagnosis matches verbatim (e.g., "adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection, including patients with Stage IIB or IIC disease" for Keytruda KEYNOTE-716).

2. Cite the NCCN Melanoma guideline version and page number. Quote: "Pembrolizumab is a Category 1 recommendation for adjuvant therapy in Stage IIB/IIC melanoma (KEYNOTE-716, 17-month improvement in recurrence-free survival, hazard ratio 0.65)." NCCN Category 1 means "based upon high-level evidence" and "uniform NCCN consensus that the intervention is appropriate."

3. Invoke plan language. Most contracts define "experimental" as not FDA-approved and not accepted as standard of care. Write: "The plan's Certificate of Coverage states experimental treatment is treatment without FDA approval or lacking acceptance by the medical community. Keytruda for Stage IIB/IIC has FDA approval (Dec 2021) and NCCN Category 1 recommendation—both criteria are met; therefore the plan's own definition excludes 'experimental' classification."

4. If Amtagvi (TIL) is denied: emphasize accelerated FDA approval (Feb 16, 2024) and NCCN Category 2A. Note that "accelerated approval" is still FDA approval under 21 CFR 314 Subpart H, binding on coverage. Cite C-144-01 trial: 36% ORR, median duration of response not reached at 33 months, in heavily pretreated population. Quote NCCN: "TIL therapy (lifileucel) is an option for patients who have progressed on anti-PD-1."

5. If Opdualag is denied: point out it is a fixed-dose combination of Opdivo (already covered) + relatlimab. RELATIVITY-047 showed superior PFS (10.2 vs 4.6 months, HR 0.78) and trend to improved OS. It is not investigational—it received standard FDA approval March 2022 and is NCCN Category 2A first-line for advanced melanoma.

2. Fighting Step-Therapy / "Try Cheaper Drug First"

Concrete steps:

1. Document clinical urgency and why delay is harmful. For advanced melanoma with rapidly growing metastases (doubling time <3 months), visceral disease, or elevated LDH, write: "Patient has AJCC M1c disease with hepatic and pulmonary metastases, LDH 450 (>ULN), ECOG 1 declining. Melanoma doubling time on CT ~6 weeks. Step-therapy delay of 3–6 months for single-agent trial risks irreversible progression, loss of performance status, and ineligibility for any therapy."

2. Cite superior efficacy data for the requested regimen. For Opdivo + Yervoy vs monotherapy: "CheckMate-067 6.5-year overall survival: Opdivo + Yervoy 52%, Opdivo alone 42%, Yervoy alone 24% (HR 0.52 for combination vs Yervoy, p<0.0001). Patient is BRAF wild-type with brain metastases—combination is NCCN Category 1 preferred first-line. Requiring monotherapy first is not step-therapy but contraindicated sequencing that sacrifices curative potential."

3. For BRAF/MEK combinations: If insurer demands dabrafenib monotherapy before allowing Tafinlar + Mekinist, cite FDA label: "The prescribing information for Tafinlar states: 'Tafinlar as a single agent is not indicated for the treatment of patients with melanoma; use Tafinlar in combination with trametinib.' Single-agent BRAF inhibitor leads to resistance via MEK pathway reactivation within 6–8 months; combination blocks resistance and is the only FDA-approved regimen." Attach label page showing no monotherapy indication for melanoma.

4. Invoke state step-therapy laws. Many states (e.g., California AB 1973, New York Part 243, Texas SB 1512) require exception to step-therapy if the preferred drug is expected to be ineffective based on clinical guidelines or patient characteristics. Write: "Under [state] Insurance Code §[cite section], a step-therapy exception is required when the health care services are expected to be ineffective based on the known clinical characteristics of the patient and the known characteristics of the drug regimen. NCCN states Opdivo + Yervoy combination is preferred for BRAF wild-type melanoma; single-agent Keytruda is an alternative but with lower response and survival. Clinical characteristics (M1c, LDH elevated, brain mets) favor combination. I request immediate exception."

5. Request peer-to-peer review urgently. In writing: "I request an expedited peer-to-peer review with a board-certified medical oncologist with melanoma expertise within 72 hours. The reviewing physician should have access to CheckMate-067, KEYNOTE-054, and NCCN Melanoma guidelines version 2.2024. I will provide references in advance."

3. Overturning Off-Label and Non-Standard Sequencing Denials

Concrete steps (neoadjuvant immunotherapy example):

1. Cite NCCN explicitly. "NCCN Melanoma guidelines (Version 2.2024, page MELA-13) list neoadjuvant systemic therapy—pembrolizumab or nivolumab + ipilimumab—as a Category 2A option for resectable clinical Stage III melanoma. Category 2A means 'based upon lower-level evidence and uniform NCCN consensus.'"

2. Attach key publications:

- SWOG S1801 (neoadjuvant + adjuvant Keytruda vs adjuvant alone): presented ASCO 2022, showed improved event-free survival. Write: "SWOG S1801 demonstrated neoadjuvant pembrolizumab improved 2-year EFS to 72% vs 49% for adjuvant-only in Stage III melanoma. Pathologic complete response rate 31%, correlates with long-term survival."

- OpACIN-neo (neoadjuvant Opdivo + Yervoy): Lancet Oncol 2020; pathologic response 78%, pCR 58%. "Neoadjuvant Opdivo + Yervoy in Stage III yielded 58% pathologic complete response—higher than adjuvant therapy can achieve—and improves surgical outcomes by debulking nodal disease."

3. Explain why neoadjuvant is medically necessary now. "Patient has bulky palpable axillary adenopathy (4 nodes, largest 6 cm). Surgical oncologist states upfront resection would require extensive dissection with high lymphedema risk. Neoadjuvant immunotherapy can shrink nodal burden, allow less morbid surgery, and provide in vivo assessment of tumor immunotherapy sensitivity. Delaying to adjuvant-only forfeits these benefits."

4. If denied for sequencing (e.g., ICI after BRAF/MEK): "DREAMseq trial compared first-line sequencing—checkpoint-first vs targeted-first—and found checkpoint-first superior in BRAF-mutant melanoma (median OS 46.8 vs 42.3 months). This trial does not conclude that patients who received targeted therapy first should be denied checkpoint therapy at progression. Patient progressed on Tafinlar + Mekinist after 11 months; Opdivo + Yervoy is now requested as second-line. Second-line checkpoint inhibitors retain activity: ~20% response rate in BRAF-mutant melanoma post-targeted therapy. Denial misconstrues DREAMseq's prospective sequencing question as prohibition of salvage."

For Imlygic intralesional therapy:

1. OPTiM trial inclusion criteria: enrolled unresectable Stage IIIB, IIIC, and IVM1a (distant skin/subcutaneous/nodal mets). FDA approval: "unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery." If insurer says "only for local disease," cite label and OPTiM: 16.3% of patients in OPTiM had Stage IV M1a—trial was positive in this group.

2. Combination rationale: NCCN lists Imlygic as compatible with checkpoint inhibitors (combination increases systemic response via abscopal effect). If denied for concurrent Keytruda, cite phase Ib data (J Immunother Cancer 2020) showing Imlygic + Keytruda well tolerated, ORR 62% in advanced melanoma.

4. Securing Biomarker Testing and Mutation-Based Therapy

Concrete steps:

1. BRAF testing denial: If insurer questions community lab BRAF result, write: "Patient's BRAF V600E mutation was identified by next-generation sequencing [name of CLIA-certified lab, CAP-accredited]. This test has FDA approval / LDT validation and >99% concordance with reference standards. NCCN Melanoma guidelines require BRAF/NRAS/cKIT mutation testing for all Stage III and IV melanoma (page MELA-8). Repeat testing at insurer-designated lab will delay BRAF/MEK therapy 3–4 weeks, during which patient's lung metastases are growing (6 new nodules on last CT). I request acceptance of the existing CLIA/CAP BRAF result or, if insurer requires confirmation, overnight courier of tumor block to insurer lab with 72-hour turnaround guarantee."

2. HLA-A\02:01 for Kimmtrak (uveal melanoma): If insurer denies coverage of HLA typing, cite FDA label: "Kimmtrak is indicated for HLA-A\02:01-positive patients. Prescribing information (Section 2.1) states HLA typing is required prior to infusion. HLA-A\02:01 testing is companion diagnostic—it is a mandatory medical service under the plan's laboratory benefit to determine drug eligibility, just as BRAF testing is covered for BRAF inhibitors." Then, after HLA typing confirms positive, if insurer still denies Kimmtrak: "Patient is HLA-A\02:01 positive [attach lab report]. IMCgp100-202 trial: overall survival 21.7 months for Kimmtrak vs 16.0 months for investigator's choice (pembrolizumab, ipilimumab, or dacarbazine); HR 0.51, p=0.0001. Uveal melanoma is refractory to standard checkpoint inhibitors (response rate <5%). Kimmtrak is the only FDA-approved therapy with proven survival benefit. NCCN Uveal Melanoma guidelines Category 1."

3. PD-L1 requirement imported from lung cancer: "KEYNOTE-054 (adjuvant Keytruda Stage III) and KEYNOTE-716 (Stage IIB/IIC) had no PD-L1 threshold—all patients enrolled regardless of PD-L1. Benefit was seen across PD-L1 <1%, 1–49%, and ≥50%. FDA approval for melanoma does not require PD-L1 testing. The plan's PD-L1 ≥50% requirement is copied from non-small cell lung cancer policy and is clinically inappropriate for melanoma."

5. Resolving Coding, Benefit, and Administrative Denials

Concrete steps:

1. Medical vs. pharmacy benefit confusion:

- Obtain written confirmation from the plan: which benefit covers Keytruda/Opdivo J-codes (J9271, J9299)? Many plans cover infused biologics under medical, but some carve out to specialty pharmacy.

- If plan bounces between benefits, write: "I have submitted prior authorization under both medical benefit (reference #123) and pharmacy benefit (reference #456). Each denial states the other benefit is responsible. Under [state] prompt pay / timely decision law, the plan must issue a determination within [15/30] days. It has been 60 days. I invoke the plan's grievance and external review process and request immediate coverage under either benefit to avoid treatment delay."

2. Inpatient-only restriction for Opdivo + Yervoy or Amtagvi:

- Opdivo + Yervoy combination is safely administered outpatient in the majority of U.S. cancer centers. If plan requires inpatient: "CheckMate-067 trial administered Opdivo + Yervoy in outpatient infusion centers. The combination's safety profile (grade 3–4 adverse events ~55–60%) is manageable with outpatient monitoring, same-day steroid administration if needed, and patient education. Inpatient administration adds \$5,000–10,000 per infusion in facility fees with no clinical benefit. NCCN does not require inpatient setting. I request authorization for outpatient administration at [infusion center] with 23-hour observation availability if needed."

- For Amtagvi TIL: initial infusion may require 7–10 day hospitalization (cell infusion + IL-2 support, monitoring for cytokine release syndrome). If insurer approves Amtagvi but denies inpatient stay, cite C-144-01 protocol and label: "Prescribing information Section 2.2: patients should be hospitalized for a minimum of 24 hours following the lifileucel infusion and until clinically stable. Mean hospital stay in C-144-01 was 9 days. Outpatient TIL infusion is not feasible and is unsafe."

3. Formulary exclusion (e.g., Opdualag not on formulary):

- Check plan's formulary exception process. Write: "Opdualag (nivolumab + relatlimab fixed-dose) is not listed on the plan formulary. However, patient has advanced melanoma with PD on Keytruda monotherapy. RELATIVITY-047 showed dual checkpoint blockade (anti-PD-1 + anti-LAG-3) improves PFS. The plan covers Opdivo + Yervoy combination (two separate infusions); Opdualag is a single-vial convenience formulation with similar mechanism and equivalent cost (~\$15,000/month). I request formulary exception under the plan's non-formulary drug policy. Alternative is Opdivo + Yervoy, which the plan must then approve at equivalent cost."

---

General Appeal Strategy

Regardless of the specific denial reason, every appeal should include:

1. A cover letter summarizing the request, citing 2–3 top-tier references (NCCN Category, FDA approval, pivotal trial), and invoking the plan's appeal rights and state/federal timelines.

2. A detailed letter of medical necessity from the treating oncologist—2–3 pages, with:

- Patient history (stage, mutation, prior lines, performance status).

- Why this regimen is standard of care (NCCN Category 1 or 2A; FDA-approved indication).

- Why alternatives are inferior or inappropriate (e.g., "single-agent checkpoint inhibitor has 40% lower 5-year OS than combination in this patient's risk group").

- Specific harms of delay (progression risk, loss of surgical window, decline in performance status precluding future therapy).

3. Attachments:

- FDA prescribing information (highlight indication and approval date).

- NCCN guideline excerpt (screenshot or PDF of the relevant algorithm page and footnotes).

- Key trial publications (title page + survival curves or primary endpoint table).

- Pathology and molecular reports (BRAF mutation, HLA typing, PD-L1 if relevant).

- Radiology reports documenting metastatic disease or response/progression.

4. Cite external review rights early. In the first appeal, write: "If this internal appeal is denied, I will immediately request independent external review under [state law / ERISA / ACA §2719]. The external reviewer will apply NCCN guidelines and FDA labeling as the standard of care. I provide these citations now to expedite resolution and avoid external review costs to the plan."

5. Escalate to state regulators if needed. If the plan delays or issues boilerplate denials, file a complaint with your state Department of Insurance (or Department of Managed Health Care in California). Attach denial letters and timeline. Regulators can compel expedited review.

---

When to Involve Legal or Patient Advocacy Support

• Amtagvi (TIL), Kimmtrak, or other newly approved therapy denied as experimental: These high-cost, highly specialized therapies ($500,000+ for TIL) face near-universal initial denial. Consider engaging a patient advocacy organization (Aim at Melanoma Foundation, Melanoma Research Foundation) or a healthcare attorney experienced in coverage appeals. Some law firms work on contingency or pro bono for FDA-approved cancer therapies.
• Multiple denials for the same therapy: If you have appealed internally, gone to external review, and still face denial, legal action (state court breach of contract, bad faith denial, or ERISA lawsuit in federal court) may be necessary. ERISA cases are complex; consult an ERISA attorney.
• Clinical trial access denials: If mRNA-4157 + Keytruda or other investigational combination in a clinical trial is denied, many states require coverage of "routine patient care costs" in cancer trials. Cite your state's clinical trial coverage law (e.g., California Health & Safety Code §1370.6).

---

What We Do

We help patients and oncology practices draft appeals, compile the citations above, and navigate insurance bureaucracy for melanoma immunotherapy and targeted therapy denials. We provide detailed, evidence-based letters of medical necessity, organize peer-to-peer reviews, and support external review submissions. Our service is built by people who have fought these denials—and won—using the trial data, NCCN updates, and FDA approvals that plans are required to respect. We don't replace your oncologist or lawyer, but we translate clinical evidence into the language insurance medical directors understand, and we track every deadline so nothing falls through the cracks.

---

Sources

1. NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 2.2024 (and updates). National Comprehensive Cancer Network. Available at NCCN.org (free registration).

2. NCCN Clinical Practice Guidelines in Oncology: Uveal Melanoma. Version 1.2024. NCCN.

3. Keytruda (pembrolizumab) Prescribing Information. Merck Sharp & Dohme Corp. Revised 2023. FDA approval letters: Sep 2014 (advanced),